Literature DB >> 17072575

Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward.

A H Gifford1, K B Kirkland.   

Abstract

Nosocomial diarrhea caused by Clostridium difficile causes significant morbidity and mortality in an increasing proportion of hospitalized patients annually. This case-control study of patients admitted to the hematology-oncology ward of a tertiary academic medical center over a 2-year period demonstrates that patients with Clostridium difficile-associated diarrhea (CDAD) were 22 times more likely than ward-matched controls with diarrhea to have received any antibiotic either during hospitalization or in the month preceding admission (p < 0.005), and they were nearly three times as likely as controls to have received a cephalosporin during the same period (p < 0.005). Diarrhea among lung cancer patients was approximately three times more likely to be caused by this organism than to be due to other causes (p = 0.04). A trend towards CDAD patients receiving higher numbers of different antibiotics during hospitalization (3.3 vs. 2.6, 95%CI -1.42-0.02, p = 0.06) was noted. Administration of interleukin-2 either during hospitalization or in the 30 days preceding admission was seven times more likely to have occurred in CDAD cases (p = 0.04), raising the question of whether or not this agent increases risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072575     DOI: 10.1007/s10096-006-0220-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

1.  Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients.

Authors:  K Hornbuckle; A Chak; H M Lazarus; G S Cooper; L A Kutteh; R Gucalp; P S Carlisle; J Sparano; P Parker; R A Salata
Journal:  Ann Oncol       Date:  1998-03       Impact factor: 32.976

2.  Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics.

Authors:  E Blot; M-C Escande; D Besson; F Barbut; C Granpeix; B Asselain; M-C Falcou; P Pouillart
Journal:  J Hosp Infect       Date:  2003-03       Impact factor: 3.926

3.  Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital.

Authors:  M J Schwaber; A Simhon; C Block; V Roval; N Ferderber; M Shapiro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-01       Impact factor: 3.267

4.  Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans.

Authors:  Anna M Buchner; Amnon Sonnenberg
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

5.  Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation.

Authors:  M Dettenkofer; W Ebner; H Bertz; R Babikir; J Finke; U Frank; H Rüden; F D Daschner
Journal:  Bone Marrow Transplant       Date:  2003-05       Impact factor: 5.483

6.  Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay.

Authors:  David K Turgeon; Thomas J Novicki; John Quick; LaDonna Carlson; Pat Miller; Bruce Ulness; Anne Cent; Rhoda Ashley; Ann Larson; Marie Coyle; Ajit P Limaye; Brad T Cookson; Thomas R Fritsche
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

7.  Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients.

Authors:  M Emoto; T Kawarabayashi; M D Hachisuga; F Eguchi; K Shirakawa
Journal:  Gynecol Oncol       Date:  1996-06       Impact factor: 5.482

8.  Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.

Authors:  C R Clabots; S Johnson; M M Olson; L R Peterson; D N Gerding
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

9.  Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens.

Authors:  A Husain; L Aptaker; D R Spriggs; R R Barakat
Journal:  Gynecol Oncol       Date:  1998-10       Impact factor: 5.482

10.  Clostridium difficile toxins A and B inhibit human immune response in vitro.

Authors:  W Däubener; E Leiser; C von Eichel-Streiber; U Hadding
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

View more
  12 in total

1.  The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients.

Authors:  Inge C Gyssens; Winfried V Kern; David M Livermore
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

2.  Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy.

Authors:  Young Kyung Yoon; Min Ja Kim; Jang Wook Sohn; Hye Suk Kim; Yoon Ji Choi; Jung Sun Kim; Seung Tae Kim; Kyong Hwa Park; Seok Jin Kim; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Yong Park
Journal:  Support Care Cancer       Date:  2014-03-05       Impact factor: 3.603

Review 3.  Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Gut Microbes       Date:  2013-12-11

4.  Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Authors:  S L Pett; C Carey; E Lin; D Wentworth; J Lazovski; J M Miró; F Gordin; B Angus; M Rodriguez-Barradas; R Rubio; G Tambussi; D A Cooper; S Emery
Journal:  HIV Med       Date:  2010-08-31       Impact factor: 3.180

Review 5.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

6.  Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.

Authors:  Isabel Ruiz-Camps; Benito Almirante; Thais Larrainzar-Coghen; Dolors Rodríguez-Pardo; Pere Barba; Juan Aguilar-Company; Virginia Rodríguez; Gloria Roig; Carmen Ferrer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-02       Impact factor: 3.267

7.  Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.

Authors:  Christine M Bassis; Casey M Theriot; Vincent B Young
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

8.  Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study.

Authors:  Bojana Milenković; Vesna Šuljagić; Aneta Perić; Viktorija Dragojević-Simić; Olivera Tarabar; Milomir Milanović; Vesna Putić; Diana Tomić; Branislava Miljković; Sandra Vezmar Kovačević
Journal:  Eur J Hosp Pharm       Date:  2021-02-12

9.  Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?

Authors:  Matthias G Hautmann; Matthias Hipp; Oliver Kölbl
Journal:  Radiat Oncol       Date:  2011-08-01       Impact factor: 3.481

10.  Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients.

Authors:  Thorsten Fuereder; Danjel Koni; Andreas Gleiss; Michael Kundi; Athanasios Makristathis; Christoph Zielinski; Christoph Steininger
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.